Investments

AIMM Therapeutics

Business: The company aims to develop high quality human monoclonal antibodies to treat diseases with a high, unmet medical need. AIMM exploits and develops new, innovative technologies to generate stable monoclonal cell lines of human antibody-producing B cells against infectious agents.

Founded: 2004
Website AIMM Therapeutics

AIMM

It’s business stupid

What is it with the Dutch that they have such difficulty grabbing business opportunities in a changing world? We have the brains, we have the money and the opportunities are plenty. Still, during the last 40 years hardly any company of substantial size has emerged next to the old industry in the AEX. Oil, food, materials and financial services dominate the landscape.

We have left the environmental challenges to environmentalists, rather then building innovative businesses in solar or wind energy to help face them. We have exported our knowledge on agriculture around the world, and now that we can more intelligently engineer crops we let the opportunity pass due to invalid arguments around GMOs. Now that “kweekersrecht” is being substituted by patent law we complain instead of adapt.

Continue

This site conforms to the following standards: